Rozenman Mary M. 4
4 · Aimmune Therapeutics, Inc. · Filed Feb 5, 2018
Insider Transaction Report
Form 4
Rozenman Mary M.
See Remarks
Transactions
- Sale
Common Stock, $0.0001 par value
2018-02-01$34.95/sh−2,300$80,385→ 4,421 total - Exercise/Conversion
Common Stock, $0.0001 par value
2018-02-01$3.02/sh+6,592$19,921→ 6,721 total - Exercise/Conversion
Stock Option (right to buy)
2018-02-01−6,592→ 107,243 totalExercise: $3.02Exp: 2025-04-17→ Common Stock (6,592 underlying) - Sale
Common Stock, $0.0001 par value
2018-02-01$35.58/sh−4,292$152,703→ 129 total
Footnotes (4)
- [F1]The sales reported in the Form 4 were effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $34.19 to $35.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F3]The transaction was executed in multiple trades in prices ranging from $35.20 to $35.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F4]The option is immediately exercisable in full or in part. The shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from February 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.